Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01493843
Completed
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without pictilisib in particpants with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Particpants will be randomized to receive 4 cycles of carboplatin (C)/paclitaxel (P) and either pictilisib or placebo, with (participants with non-squamous NSCLC) or without (participants with squamous... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Gabrail Cancer Center, Canton, Ohio +2 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
NCT01160601
Completed
This is a randomized, open-label, multicenter, phase 2 study comparing Paclitaxel/Carboplatin with or without bavituximab in patients that have previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2017
Locations: Gabrail Cancer Center, Canton, Ohio +2 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
NCT00879359
Completed
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment of endometrial cancer. Avastin is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) produced by Genentech, Inc. Avastin is an antibody directed against vascular endothelial gr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/16/2017
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Endometrial Carcinoma
Register for Updates
Surgery in Treating Children With Neuroblastoma
NCT00003119
Completed
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/09/2017
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +8 locations
Conditions: Neuroblastoma
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Completed
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2017
Locations: Wood County Oncology Center, Bowling Green, Ohio +40 locations
Conditions: Melanoma (Skin)
Register for Updates
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00874107
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with bevacizumab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2017
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
NCT00980551
Withdrawn
The investigators are testing subtenon carboplatin in combination with vincristine and topotecan given by vein in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back (recurrent) or is resistant to other treatment (refractory). The goals of this study are: * To decide if the drug combination is a useful treatment for recurrent or refractory retinoblastoma * To test the safety of the drug combination and to see what kind of effects (good and ba... Read More
Gender:
ALL
Ages:
10 years and below
Trial Updated:
02/28/2017
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Retinoblastoma
Register for Updates
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Akron, Ohio +11 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Register for Updates
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
NCT00936702
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2017
Locations: Wood County Oncology Center, Bowling Green, Ohio +26 locations
Conditions: Carcinoma of Unknown Primary Origin
Register for Updates
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
NCT02087241
Terminated
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2017
Locations: Research Site, Cincinnati, Ohio
Conditions: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Register for Updates
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
NCT02319889
Terminated
This pilot clinical trial studies stereotactic body radiation therapy followed by combination chemotherapy in treating patients with non-small cell lung cancer. Stereotactic body radiation therapy is a specialized radiation therapy that delivers one to five high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue than conventional radiation. Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2017
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
Register for Updates
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
NCT00906282
Completed
The purpose of this multi-center Phase II trial is to examine the impact of pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and III non-squamous NSCLC. Because patients with non-squamous type NSCLC have been shown to have better survival rates than patients with squamous tumors when given pemetrexed with a platinum agent, only patients with non-squamous NSCLC (adenocarcinoma, large cell, and undifferentiated), not including squamous histology, will be al... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2017
Locations: Oncology Hematology Care, Cincinnati, Ohio
Conditions: Non Small Cell Lung Cancer
Register for Updates